Predictive Oncology Inc. (POAI)
1.50
0.00 (0.00%)
At close: Feb 20, 2025, 3:59 PM
1.49
-0.33%
After-hours: Feb 20, 2025, 04:46 PM EST
undefined% (undefined)
| Bid | 1.42 |
| Market Cap | 9.97M |
| Revenue (ttm) | - |
| Net Income (ttm) | - |
| EPS (ttm) | -2.96 |
| PE Ratio (ttm) | -0.51 |
| Forward PE | n/a |
| Analyst | Buy |
| Ask | 1.49 |
| Volume | 340,444 |
| Avg. Volume (20D) | 2,174,494 |
| Open | 1.49 |
| Previous Close | 1.50 |
| Day's Range | 1.39 - 1.53 |
| 52-Week Range | 0.55 - 3.76 |
| Beta | undefined |
About POAI
Predictive Oncology Inc., a knowledge-driven company, focuses on developing personalized cancer therapies using artificial intelligence (AI) primarily in the United States. The company operates in four segments: Helomics, zPREDICTA, Soluble, and Skyline. The Helomics segment offers clinical testing services comprising tumor drug response testing and genomic profiling tests; and contract research services through patient-centric drug discovery usi...
Industry Medical - Instruments & Supplies
Sector Healthcare
IPO Date May 3, 2010
Employees 34
Stock Exchange NASDAQ
Ticker Symbol POAI
Analyst Forecast
According to 2 analyst ratings, the average rating for POAI stock is "Buy." The 12-month stock price forecast is $3, which is an increase of 100.67% from the latest price.
Buy 50.00%
Hold 0.00%
Sell 0.00%
2 days ago
-23.08%
Predictive Oncology shares are trading lower after...
Unlock content with
Pro Subscription
3 days ago
+20.37%
Predictive Oncology shares are trading higher after the company reported results from utilizing AI for drug repurposing.
